Ripazepam (CI-683): double-blind comparison with placebo in anxious patients. 1976

J J Schneyer, and L I Goodman, and L A Borgen

Thirty anxious, neurotic patients were treated in a general practice setting with single-blind placebo for one week followed by two weeks of double-blind treatment with either placebo or 40 or 80 mg/day ripazepam (CI-683), a new potential antianxiety agent of the pyrazolodiazepinone series. As rated by both physician and patient, ripazepam was found significantly superior to placebo at both dosage levels. Some evidence of greater improvement at 80 mg/day than at 40 mg/day was also obtained. The drug appeared to be well tolerated, with side effects reported by only four patients.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001007 Anxiety Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS. Angst,Anxiousness,Hypervigilance,Nervousness,Social Anxiety,Anxieties, Social,Anxiety, Social,Social Anxieties

Related Publications

J J Schneyer, and L I Goodman, and L A Borgen
January 1979, The Journal of international medical research,
J J Schneyer, and L I Goodman, and L A Borgen
January 1983, Psychopharmacology,
J J Schneyer, and L I Goodman, and L A Borgen
January 1985, British journal of clinical pharmacology,
J J Schneyer, and L I Goodman, and L A Borgen
November 1986, Angiology,
J J Schneyer, and L I Goodman, and L A Borgen
January 1984, Neuropsychobiology,
J J Schneyer, and L I Goodman, and L A Borgen
December 1992, The Journal of clinical psychiatry,
J J Schneyer, and L I Goodman, and L A Borgen
March 1986, The American journal of medicine,
J J Schneyer, and L I Goodman, and L A Borgen
September 1981, The Journal of clinical psychiatry,
J J Schneyer, and L I Goodman, and L A Borgen
December 1992, Clinical neuropharmacology,
Copied contents to your clipboard!